期刊
NETHERLANDS HEART JOURNAL
卷 28, 期 7-8, 页码 406-409出版社
BOHN STAFLEU VAN LOGHUM BV
DOI: 10.1007/s12471-020-01429-7
关键词
COVID-19; Coronavirus; SARS-CoV-2; Chloroquine; QT prolongation; Electrocardiogram
Background In the battle against the SARS-CoV-2 pandemic, chloroquine has emerged as a new potential therapeutic option for the treatment of infected patients. A safety consideration for the application of chloroquine is its QTc-prolonging potential. Thus far, no data are available on the QTc-prolonging potential of chloroquine in COVID-19 patients. Objective To assess the degree of chloroquine-induced QTc prolongation in hospitalised COVID-19 patients. Methods A baseline electrocardiogram (ECG) and ECGs recorded during chloroquine treatment were retrospectively collected in patients suspected of having COVID-19. The QTc interval was calculated by computerised and manual interpretation. Baseline and follow-up QTc intervals were compared using the paired samples t-test. Results A total of 95 patients had a baseline ECG recording and at least one ECG recording during chloroquine therapy. Chloroquine treatment resulted in a mean QTc prolongation of 35 & x202f;ms (95% CI 28-43 & x202f;ms) using computerised interpretation and 34 & x202f;ms (95% CI 25-43 & x202f;ms) using manual interpretation. No torsade de pointes was observed during chloroquine treatment. After manual review, 22 patients (23%) had a QTc interval exceeding 500 & x202f;ms during chloroquine treatment. None of these patients had a prolonged QTc interval prior to the initiation of chloroquine treatment. Conclusions Chloroquine significantly prolongs the QTc interval in a clinically relevant matter. This highlights the need for ECG monitoring when prescribing chloroquine to COVID-19 patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据